

At page 19, line 38, please delete "lymphmokynes" and insert ---
lymphokynes---;

IN THE CLAIMS

Please amend the Claims as follows:

11. (Twice Amended) A method of treating a condition or disease in a human involving tissue selected from the group consisting of underperfused tissue and pathological tissue which will benefit from the treatment by the administration of an agent selected from the group consisting of a medicinal agent and a therapeutic agent and combinations thereof, which is suitable for treating said tissue, the method [mammal] comprising administering to the human [mammal] a therapeutically effective dosage amount of a pharmaceutical composition comprising a therapeutically effective amount of the [an] agent [selected from the group consisting of a medicine and a therapeutic agent and combinations thereof] to treat the disease or condition involving tissue selected from the group consisting of underperfused tissue and pathological tissue, and a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts and combinations thereof sufficient to facilitate the transport and penetration of the agent through the tissue at a site to be treated through the cell membranes into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10mg[/70kg person.] and less than 3000mg.

122. (Twice Amended) A dosage amount of a pharmaceutical composition in a suitable pharmaceutically acceptable excipient for treating infection[,] involving underperfused tissue and pathological tissue in humans, said dosage amount

03 comprising a therapeutically effective amount of an agent selected from the group consisting of antibiotics, antibacterials, antimicrobials and combinations thereof with or without ascorbic acid and a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts and combinations thereof to facilitate the transport of the agent at a site to be treated by the agents passing through the tissue through the cell membranes into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10mg[/70kg person].

04 4/ 151. (Twice Amended) A dosage amount of a pharmaceutical composition in a suitable pharmaceutically acceptable excipient for treating infections surrounding implants involving underperfused tissue and pathological tissue in a patient, said dosage amount comprising a therapeutically effective amount of an antibiotic agent for treating the infected tissue surrounding the implant and a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts and combinations thereof to facilitate the transport and penetration of the agent at a site to be treated by the agents passing through the tissue through the cell membranes into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10mg[/70kg person.] and less than 3000mg.

05 5/ 151. (Twice Amended) A method of treating infection[,] involving underperfused tissue and pathological tissue in humans, the method comprising the administration of a therapeutically effective amount of an agent selected from the group consisting of antibiotics, antibacterials, antimicrobials and

78

combinations thereof with or without ascorbic acid and a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts and combinations thereof to facilitate the transport and penetration of the agent at a site to be treated by the agents passing through the tissue through the cell membranes into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10mg[/70kg person.] and less than 3000mg.

De 6 261. (Twice Amended) A method of treating infections surrounding implants involving underperfused tissue and pathological tissue in a patient, the method comprising the administration of a therapeutically effective amount of an antibiotic for the infected tissue surrounding the implant and a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts and combinations thereof to facilitate the transport and penetration of the agent at a site to be treated by the agents passing through the tissue through the cell membranes into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10mg[/70kg person.] and less than 3000mg.

8 261. (Twice Amended) A dosage amount of a pharmaceutical composition in a suitable pharmaceutically acceptable excipient for the prevention of topical infection[,] involving underperfused tissue and pathological tissue in humans, said dosage amount comprising an effective amount of an anti-metabolite agent for preventing topical infection and a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts and combinations thereof to facilitate the transport and penetration of the agent

at a site to be treated by the agents passing through the tissue through the cell membranes into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10mg[/70kg person.] and less than 3000mg.

*Sept
Df*

263. (Twice Amended) A method of preventing a topical infection[,] involving underperfused tissue and pathological tissue in humans, the method comprising the administration of an effective amount of an anti-metabolite agent and a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts and combinations thereof to facilitate the transport and penetration of the agent at a site to be treated by the agents passing through the tissue through the cell membranes into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10mg[/70kg person.] and less than 3000mg.

REMARKS

Claims 11, 122, 123, 151, 187, 216, 218 and 261-264 remain the Application. Some of these claims have been amended with a view of more clearly defining the invention and to overcome the grounds of rejection by the Examiner under 35 U.S.C. §112, second paragraph, without adding new subject matter.

Applicants acknowledge that the Examiner has withdrawn rejections under 35 U.S.C. §102 and §112, first paragraph, in view of Applicants' arguments filed December 16, 1996. Applicants will now further address the rejection of the Examiner under 35 U.S.C. §103.

80